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Abstract
p53 is important in the development of hepatocellular carcinoma (HCC) and in therapeutic
approaches, but the mechanism whereby it inhibits HCC growth is still unclear. The aim of the
present study was to establish a HCC cell system in which p53 levels can be regulated. Full-length
wild-type p53 cDNA obtained by PCR was cloned into a retroviral response vector controlled by
the tetracycline responsive element (RevTRE-p53). The regulatory vectors RevTet-Off and
RevTRE-p53 were transfected into a packaging cell line, PT67. Hep3B cells in which the p53 gene
was deleted were infected with RevTet-Off viral particles from the PT67. Three G418-resistant cell
clones with high luciferase expression and low background were infected with RevTRE-p53. By
screening dozens of RevTRE-p53-infected clones with hygromycin we identified the one with the
highest expression of p53 and the lowest background after doxycycline treatment. The results
showed that p53 expression in this cell clone could be simply turned on or off by removing or
adding doxycycline. Furthermore, it was found that the level of p53 protein was negatively and
sensitively related to the doxycycline concentration. In conclusion, we have established a HCC cell
line in which p53 expression can be switched on or off and regulated in a dose- and time-dependent
manner.
Introduction
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies worldwide and is estimated to cause
over one million deaths every year [1]. Risk factors have
been identified, including chronic infection with hepatitis
B and C viruses and exposure to aflatoxin B1, but the exact
molecular mechanisms of carcinogenesis have not been
completely defined. Mutation or deletion of the p53 gene,
which plays an important role in cell growth, division and
apoptosis by acting as a transcription factor or by forming
complexes with other proteins [2], are frequently detected
in HCC [3]. In addition, loss of the functional p53 gene is
associated with lower cellular differentiation and poor
prognosis [4]. Hence, restoration of a wild-type p53 gene
is an attractive approach to the treatment of HCC [5].
Tight quantitative and temporal control of gene expres-
sion is very useful for basic biological and medical
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systems have been developed such as hormones, heavy
metal ions and heat shock [6]. However, most of them are
limited by low and nonspecific induction, toxic effects of
the inducing agents, high basal levels of gene expression
under non-induced conditions and pleiotropic effects [7].
The tetracycline (tet)-regulated gene expression system
overcomes many of the problems of other inducible sys-
tems [8,9] and has been widely utilized in mammalian
cell culture [10], transgenic mice [11] and other species
[12]. Furthermore, the retrovirus-mediated tet-regulated
gene expression system (RevTet-Off/On) combines the
advantages of retroviral transfer with those of tet-regula-
tion and allows faster and more efficient establishment of
regulated gene expression in a wide variety of cell types
[13]. In the RevTet-Off system, transcription of the gene of
interest is turned off in the presence of tetracycline or dox-
ycycline (a derivative of tetracycline). In contrast, tran-
scription of this gene is turned on in the presence of
tetracycline or doxycycline in the RevTet-On system.
Loss of p53 function by mutation not only results in the
malignant transformation of cells but also enhances
resistance to anticancer drugs and radiation [14]. Studies
on human tumors carrying mutated or deleted p53 show
that the introduction of exogenous wild-type (wt) p53
could lead to apoptotic death of the tumor cells and effec-
tively inhibit their growth [15]. It is therefore important to
gain better insight into p53 function in HCC. We there-
fore cloned the wt p53 gene from a human hepatoblast-
oma cell line, HepG2, into a human hepatocellular cell
line, Hep3B, using a retrovirus-mediated tet-regulated
gene expression system (RevTet-Off) and established a
HCC cell line with tightly controllable, doubly-stable
expression of the wt p53 gene.
Materials and methods
RevTet-Off System
The RevTet-Off System was purchased from Clontech Lab-
oratories (Palo Alto, CA). It is a complete retroviral gene
expression system including a retroviral regulatory tTA
vector (pRevTet-Off), a retroviral response vector (pRev-
TRE), a control vector (pRevTRE-Luc) and a packaging cell
line (PT67).
Cell lines and culture
Hep3B and HepG2 cells were purchased from the Ameri-
can Type Culture Collection. The Hep3B cells were
derived from a human HCC deficient in p53 [16], the
HepG2 cells from a human hepatoblastoma expressing wt
p53 [17]. PT67 packaging cells were derived from an NH/
3H3-based line expressing the 10A1 virus envelope [18].
All cells were grown in Dulbecco's modified Eagles's min-
imal essential medium with high glucose (Invitrogen,
Carlsbad, California) supplemented with 10% fetal
bovine serum (Clontech, Palo Alto, CA) and incubated at
37°C in a humidified atmosphere containing 95% air and
5% carbon dioxide.
Reagents
G418 (Clontech, Palo Alto, CA) was prepared as a 10 mg/
ml stock solution. Hygromycin B was available from
Clontech as a stock solution (50 mg/ml). Both were stored
at 4°C. Aliquots of 1 mg/ml Doxycyclin (Clontech, Palo
Alto, CA) were stored in the dark at -20°C.
Construction of the RevTRE-p53 plasmid
The full-length cDNA of wt p53 was obtained from the
HepG2 cells by RT-PCR. The PCR primers were as follows:
5'-TTA AGC TTT TTG CGT TCG GGC TGG GAG C-3' and
5'-CGA TCG ATA TGG TGG CAT GAA CCT GTG G-3',
which contained restriction sites for Hind III and Cal I
respectively. The resulting PCR products were further puri-
fied with a QIAquick gel extraction kit (Qiagen, Valencia,
CA) according to the manufacturer's instructions. The full-
length p53 cDNA was cloned into the pRevTER vector
using the restriction enzymes Hind III/Cla I.
Transformation, purification and identification of 
retrovirus plasmids
The retrovirus vectors provided in the RevTet-Off System
and recombinant pRevTRE-p53 plasmid were trans-
formed into E. coli (DH5α). Plasmid DNA was purified
using a QIAprep mini kit (Qiagen, Valencia, CA) accord-
ing to the manufacturer's instructions. The purified plas-
mids were digested with the restriction enzymes Hind III
and Cla I (Invitrogen, Carlsbad, California) to confirm the
insert and the vector.
Sequence analysis of the recombinant pRevTRE-p53 
plasmid
The purified pRevTRE-p53 plasmid was sequenced with
an ABI PRISM BigDye Terminator Cycle Sequencing kit
(PE Applied Biosystems, Foster City, CA) according to the
manufacturer's protocol. A pair of primers were designed
for sequencing pRevTRE-p53: 5'-AAG CTT TTT GCG TTC
GGG CTG GGA GC-3' and 5'-ATC GAT ATG GTG GCA
TGA ACC TGT GG-3'. Recombinant pRevTRE-p53 plas-
mid was purified from E. coli with a QIAGEN Plasmid
Midi kit (Qiagen, Valencia, CA).
Package of retroviral plasmids and recombinant pRevTRE-
p53 plasmid
PT67 cells were transfected with the pRevTet-Off, pRev-
TRE-Luc or pRevTRE-p53 plasmids using Lipofectamine
Reagent (Invitrogen, Carlsbad, California) according to
the manufacturer's instructions. The transfected cells were
selected in 600 µg/ml G418 or 400 µg/ml hygromycin for
2 weeks and the selective media were replaced every 4
days. Well-separated antibiotic-resistant clones werePage 2 of 8
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24-well plates in selective medium. The cells were then
transferred to larger culture vessels before confluence, and
aliquots of early passages of cells (1 × 106) were frozen in
liquid nitrogen.
Determination of viral titer
The supernatant from virus-containing PT67 cells was fil-
tered through a 0.45 µm filter and added to Hep3B cells
in the presence of 4 µg/ml polybrene (Sigma Chemical
Co. St. Louis, MO). To determine the viral titer, infection
of six 10-fold serial dilutions was performed in 6-well
plates. The medium was replaced 6 h after infection. Three
serial infections were performed. Forty-eight hours after
infection, Hep3B cells were subjected to selection by
G418 (0.5 mg/ml) or hygromycin (0.05 mg/ml) for one
week. The viral titer corresponded to the number of colo-
nies developed at the highest dilution.
Infection of Hep3B cells by RevTet-Off virus
Hep3B cells were infected with supernatant from fresh
PT67 cells containing RevTet-Off virus and selected with
G418 as described above. The isolated G418-resistant
clones were transferred to a 24-well plate with cloning cyl-
inders. Before confluence, the cells were transferred into
larger culture vessels.
Screening for inducible G418-resistant clones by RevTRE-
Luc virus
The pRevTRE-Luc control vector was constructed by clon-
ing the luciferase gene into the Hind III/Cal I sites in pRev-
TRE. G418-resistant clones infected with RevTRE-Luc
virus were selected by screening luciferase expression. For
each clone, two additional cultures in wells of a 6-well
plate were deployed as a test plate for screening. Infection
by the RevTRE-Luc virus was performed as described pre-
viously. Twenty-two hours after infection, 1 µg/ml doxy-
cycline (Dox) was added to one of the two test wells.
Luciferase activity was analyzed using a luciferase assay
system kit (Promega Corporation, Madison) according to
manufacturer's instructions.
Infection of G418-resistant clones by RevTRE-p53 virus
The selected G418-resistant clones were infected with
supernatant from PT67 cells containing RevTRE-p53
virus. The clones were selected with hygromycin for two
weeks as described previously. Healthy hygromycin-resist-
ant clones were individually transferred to a 24-well plate
with cloning cylinders and propagation was continued in
selective medium. Aliquots of early passages of hygromy-
cin-resistant cells (1 × 106) were frozen in liquid nitrogen.
Reverse transcription-polymerase chain reaction (RT-
PCR) analysis
Total RNA was extracted from cells using a RNeasy Mini
kit (Qiagen, Valencia, CA) according to the manufac-
turer's instructions and reverse-transcribed to cDNA with
a First-Strand cDNA Systhesis Kit (Amersham Biosciences,
Selangor Darul Ehsan, Malaysia). The neomycin gene and
p53 cDNA were amplified by PCR, generating a 382-bp
fragment of the neomycin gene (forward primer: 5'-TCC
TGT CAT CTC ACC TTG CTC C-3' and reverse primer: 5'-
GCA ATA TCA CGG GTA GCC AAC G-3'); a 282-bp cDNA
fragment of p53 (5'-TAC ATG TGT TAA CAG TTC CTG CA-
3' and 5'-TTC TGA CAA CGA TCG GAG GA-3'), or a 114-
bp fragment of β-microglobulin gene (5'-ACC CCC ACT
GAA AAA GAT GA-3' and 5'-ATC TTC AAA CCT CCA TGA
TG-3') that served as an internal standard for RNA integ-
rity and equal gel loading. Thermocycling was carried out
at 94°C for 3 min and 30 amplification cycles of 94°C for
30 s, 62°C for 30 s and 72°C for 1 min, followed by 72°C
for 7 min. The PCR products were electrophoresed in a
1.2% agarose gel and the cDNA fragments were stained
with ethidium bromide and visualized under an Ultravio-
let Transilluminator (UVP Inc.Upland, CA).
Western blot
Cells were lysed in extraction buffer and 20 µg/ml of pro-
tein were subjected to 12% SDS-polyacrylamide gel elec-
trophoresis. The proteins were transferred
electrophoretically on to nitrocellulose membranes
(Amersham, Piscataway, NJ). The membranes were
probed with a monoclonal mouse anti-human p53 anti-
body (1:1000) (Santa Cruz, CA) and β-actin (1:1500)
(Santa Cruz, CA) and were then incubated with goat anti-
mouse IgG-HRP antibody (1:2000) (Santa Cruz, CA). The
signals were detected using an enhanced chemilumines-
cence system.
Results
Identification of recombinant RevTRE-p53 plasmids by 
restriction enzymes
The sizes of pRevTet-Off, pRevTRE, the recombinant
pRevTRE-p53 plasmid and the cDNA fragment of p53
were 7.8 Kb, 6.5 Kb, 8.6 Kb and 2.1 Kb, respectively. The
RevTRE-p53 plasmid was cleaved with Hind III and Cal I
and fragments of 2.1 Kb and 6.5 Kb were generated.
Restriction enzyme mapping showed that the full-length
p53 cDNA had been successfully cloned into the Hind III/
Cla I sites in the pRevTRE vector, and the sizes of the
pRevTet-Off and pRevTRE-p53 fragments were consistent
with expectation (Fig. 1).
Analysis of recombinant RevTRE-p53 plasmid sequence
To confirm the sequence and orientation of the inserted
p53 cDNA in the pRevTRE vector, the purified recom-
binant pRevTRE-p53 plasmid was verified by sequencing.Page 3 of 8
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entire open reading frame coding for the p53 protein.
Sequencing results suggested that the inserted cDNA was
identical to the human p53 gene published by GenBank
(Accession number: X54156).
Selection of high titer packaging cell clones
After transfection with the purified RevTet-Off, RevTRE-
p53 and RevTRE-Luc plasmids, PT67 cells were selected
with G418 or hygromycin for two weeks. The antibiotic-
resistant clones were individually isolated with cloning
discs. The viral titers were determined by infecting Hep3B
cells with 6 × 10-fold serial diluted virus-producing media
from the PT67 clones and showed 5 × 104, 3 × 104, and 6
× 104 colony forming units for RevTet-Off, RevTRE-p53
and RevTRE-Luc, respectively. The highest titer clones
were selected for further experiments.
Selection-stable expression of Hep3B/RevTet-Off clones through 
transient infection by RevTRE-Luc virus
In an effort to establish a tet-regulated inducible cell line,
the RevTet-Off vector was first introduced into Hep3B
cells (Hep3B/RevTet-Off) by retroviral infection. The
G418-resistant clones were then infected transiently with
RevTRE-Luc virus packaged by the PT67 cells. In 32 of the
Hep3B/RevTet-Off clones the inductive efficacy of doxycy-
cline-regulated luciferase expression varied from 2 to 70
fold. Six clones showed higher levels of luciferase expres-
sion in the absence of doxycycline but different back-
grounds in the presence of 1 µg/ml Dox (Fig. 2). The
results showed that doxycycline exerted tight control over
the expression of this reporter gene in clones T13, T15 and
T23. Thus, we selected these clones for further
experiments.
Identification of doubly-stable expression in Hep3B/RevTet-Off/TRE-
p53 clones
The three selected Hep3B/RevTet-Off clones, T13, T15 and
T23, were infected with supernatant from PT67 cells con-
taining the recombinant RevTRE-p53 virus. Hygromycin-
resistant Hep3B/RevTet-off/TRE-p53 (Hep3B/tet/p53)
clones, 13T, 15T and 23T, were isolated and propagated.
We used RT-PCR to establish whether these clones exhib-
ited double-stable expression. Two sets of exploring prim-
ers were used to check if these clones are expressing both
the neomycin resistance (Neor) gene and p53 gene. The
RT-PCR results confirmed expectation (Fig. 3). Therefore,
a cell line with doubly-stable gene expression, Hep3B/tet/
p53, was established.
Selection of a tightly doxycycline-regulated p53-expression clone
To obtain a high expression, low background clone, 28
different 13T, 15T and 23T clones were analyzed by
Restriction mapping of recombinant RevTRE-p53 and vTet-Off pl smidsFigure 1
Restriction mapping of recombinant RevTRE-p53 
and RevTet-Off plasmids. The pRevTRE-p53 plasmid was 
cleaved with Hind III and Cla I. The fragments were as fol-
lows: Lane 1: 1 Kb marker, Lane 2: the fragments of the 
pRevTRE vector (6.5 Kb) and the p53 fragment (2.1 Kb). 
Lane 3: circled pRevTet-Off (7.8 Kb); Lane 4: circled pRev-
TRE-p53 (8.6 Kb).
Doxycycline-regulated luciferase activity in Hep3B/RevTet-Off clonesFigure 2
Doxycycline-regulated luciferase activity in Hep3B/
RevTet-Off clones. Hep3B/RevTet-Off clones were 
infected transiently using RevTRE-Luc retroviral particles. 
Cells were cultured in either the presence or absence of 1 
µg/ml doxycycline. Clones were assayed by the luciferase 
assay system.Page 4 of 8
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higher p53 expression in the absence of doxycycline and
higher background in its presence, but others, such as the
15T clone, displayed the opposite results. Among the
clones tested we found one (13T) that was optimal, exhib-
iting high p53 expression and low background controlled
by doxycycline; this clone was named Hep3B/tet/p53-13
(or p53-13) (Fig. 4). Semi-quantitative RT-PCR demon-
strated that the induction of p53 in the Hep3B/tet/p53-13
cells was regulated by doxycycline at the transcriptional
level (Fig. 5).
Effect of Doxycycline on Hep3B/tet/p53 cell growth
The effect of doxycycline on the growth of Hep3B/tet/p53
cells was examined by trypan blue exclusion. The result
showed 1 µg/ml doxycycline had no effect on the growth
of Hep3B/tet/p53-13 cells when compared to parental
Hep3B cells (result not shown).
Regulation of p53 expression by doxycycline
Hep3B/tet/p53-13 cells were grown in different concen-
trations of doxycycline and the expression of p53 protein
was analyzed by Western blotting. The results showed that
1- 0.00001 µg/ml doxycycline correlated negatively with
the level of p53 protein (Fig. 6). Therefore, the expression
Establishment of a cell line with doubly-stable expressionFigure 3
Establishment of a cell line with doubly-stable 
expression. Total RNA was extracted from the selected 
hygromycin-resistant clones in the absence of doxycycline. 
Two pairs of primers were used to probe the specific neo-
mycin (NeoΓ) and p53 sequences in the tested cells. Lane 
1:100 bp marker; Lane 2: HepG2 cells (carrying the wt p53 
gene); Lane 3: Hep3B cells (deletion of p53 gene); Lanes 4, 5, 
and 6: the tested 13T, 15T and 23T clones.
Selection of the optimal clone under Dox controlFigure 4
Selection of the optimal clone under Dox control. For 
each of the hygromycin-resistant clones, cells were grown 
for 24 h in the presence (Dox+) or absence (Dox-) of 1 µg/
ml Dox. The expression of p53 protein was analyzed by 
Western blotting. Lanes 1, 2: 13T (Dox+, Dox-); Lanes 3, 4: 
15T (Dox+, Dox-); Lanes 5, 6: 23T (Dox+, Dox-).
Semi-quantitative RT-PCR analysis of expression of p53 regu-lated by DoxFigure 5
Semi-quantitative RT-PCR analysis of expression of 
p53 regulated by Dox. Hep3B/tet/p53-13 (p53-13) cells 
were cultured for 24 h in the presence or absence of 1 µg/ml 
Dox and analyzed by semi-quantitative RT-PCR. Lane 1:100 
bp marker; Lane 2: Hep3B cells; Lane 3: p53-13 + 1 µg/ml 
Dox; lane 4: p53-13 + 0 µg/ml Dox. β-microglobulin (MG) 
was used as an internal control.Page 5 of 8
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dependent manner and was almost completely sup-
pressed by a 1 µg/ml concentration. A time-course analy-
sis of this regulation was performed by Western blotting.
The results showed that p53 protein expression was grad-
ually enhanced by the removal of doxycycline and
reached maximum 6 h after removal of the antibiotic (Fig.
7). In contrast, the protein expression decreased slowly
with the addition of doxycycline, becoming almost unde-
tectable 12 h after treatment (Fig. 7). Obviously, doxycy-
cline regulated p53 protein expression in a time-
dependent manner.
Discussion
The recent development of tetracycline (tet)-regulated
gene expression has multiplied the tools available for
quantitative and temporal control of exogenous genes in
different areas of biology and medicine. The first tet-regu-
lated gene expression system (tTA based) [8] consisted of
two separate plasmids: the regulatory plasmid for the tet-
transactor (tTA) and the response plasmid for the tet-oper-
ator minimal promoter driving the gene of interest. In
practice, the regulatory plasmid must first be transfected
into the target cells. However, conventional transfection
methods are not always efficient enough for transfer and
high expression of tTA is toxic to cells, probably because
of transcriptional "squelching" by the VP16 transactivator
domain in tTA [19]. Once cells that stably express tTA
have been established, the response plasmid containing
the gene of interest under the control of the tet-operator
minimal promoter must be introduced. The establish-
ment of a cell line with inducible gene expression can be
tedious and time-consuming and modifications have
been introduced to circumvent some of the limitations of
this system [20-22]. One such modification involves uti-
lizing retrovirus-mediated gene transfer instead of plas-
mid DNA transfection, thus ensuring more efficient
transduction of mammalian cells in vitro. Retroviral vec-
tors for regulated expression are powerful tools for gene
transfer since the retroviruses generally integrate as single
copies into the target cell genome. Moreover, they are
stable, need minimal effort to prepare, and generate pop-
ulations of cells that can regulate expression of the gene of
interest within weeks.
To elucidate the functions of p53 in HCC we chose a ret-
rovirus-mediated tet-regulated gene expression system,
RevTet-Off, as a tool. In the present study a full-length
cDNA of wt p53 from a human hepatoblastoma cell line,
HepG2, which expresses small amounts of wt p53, was
cloned into a retroviral response vector, pRevTRE. Subse-
quently, the target cells, Hep3B, which are derived from a
human HCC and have a homozygous deletion of the p53
gene, were first infected by the pRevTet-Off regulatory
virus and selected by an antibiotic, G418. Three of 32
tested Hep3B/RevTet-Off clones with the highest maximal
luciferase activities were then infected with the recom-
binant pRevTRE-p53 response virus. After screening with
hygromycin, the inducible, doubly-stable p53-expression
clones, Hep3B/RevTet-Off/TRE-p53 (Hep3B/tet/p53),
were identified by RT-PCR. In 28 other hygromycin-resist-
ant clones we found that the expression of p53 protein
Expression of p53 protein by Dox controlled quantitativelyFigure 6
Expression of p53 protein by Dox controlled quanti-
tatively. After p53-13 cells were cultured in 0 and 1, 0.1, 
0.01, 0.001, 0.0001, 0.00001 µg/ml Dox for 24 h, expression 
of p53 protein was examined by Western blotting. β-actin 
was served as an internal control.
Time-dependent Dox-regulated expression of p53 proteinF gure 7
Time-dependent Dox-regulated expression of p53 
protein. In the removing group, medium was removed 24 h 
after p53-13 cells were cultured in 1 µg/ml Dox (Dox+), and 
then the cells were cultured continually in the absence of 
Dox (Dox-). In the adding group, cells were cultured in the 
absence of Dox for 24 h, and then the cells were incubated 
with 1 µg/ml of Dox. The expression of p53 protein was ana-
lyzed by Western blotting. Lane1: Dox+; Lanes 2, 3, 4: Dox- 
1 h; 3 h; and 6 h; Lane 5: Dox-; Lanes 6, 7, 8: Dox+ 3 h; 6 h; 
and 12 h. β-actin was served as an internal control.Page 6 of 8
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p53 protein in the absence of doxycycline, but there was a
high basal expression in the presence of 1 µg/ml doxycy-
cline, indicating a high background. In contrast, clone 15T
had a low level of p53 protein and low background. In
contrast to clones 15T and 23T, clone 13T displayed a
higher expression level of p53 and lower background, as
demonstrated by Western blot analysis and semi-quanti-
tative RT-PCR.
We speculate that such variations of p53 expression might
result from the integration of the retrovirus. In general, the
site of integration into the host cell genome is random
[23]. When pRevTRE-p53 retroviruses integrate adjacent
to an endogenous enhancer element in the Hep3B cell
genome, this enhancer could activate p53 transcription
even in the presence of 1 µg/ml doxycycline, resulting in a
high background. At the same time, the tTA of pRevTet-
Off retroviruses might co-operate with this enhancer in
the absence of doxycycline to induce quite a high level of
p53 expression (as in clone 23T). However, if pRevTRE-
p53 retroviruses integrate into a site that is not influenced
by an endogenous enhancer, the basal expression level of
p53 could be very low as in clone 15T. No methods are
currently available for ensuring that a retrovirus integrates
at the most useful site. Therefore, it is important to screen
the hygromycin-resistant clones for the one that is opti-
mal in terms of high inducible expression and low
background.
In this study, an HCC cell line, Hep3B/tet/p53, was suc-
cessfully established with a retrovirus-mediated tet-regu-
lated gene expression system, RevTet-Off, for inducible,
doubly-stable expression of the wt-p53 gene in vitro. This
cell line is totally different from other lines established
through adenovirus-mediated transfer of the p53 gene
[24,25]. To the best of our knowledge, such a p53
expression and regulation system has not been reported in
a HCC cell line. The system of p53 expression we have
established can be controlled by doxycycline not only in
turn-on or turn-off manner, but also in a quantitative and
temporal manner. The HCC line equipped with pRevTRE-
p53 established here can be used not only to study
biological effects of the p53 gene in vitro, but also in
human gene therapy trials in the future.
It is important to investigate the translation product of the
gene of interest for its functional role in cell biology or in
therapeutic situations when this product is toxic or needs
to be maintained at appropriate levels. An inappropriately
high level of p53 may become toxic before p53 is deliv-
ered to target cells [26]. The pRevTRE-p53 system we have
established may overcome this problem since the
activation of p53 expression can be controlled quantita-
tively and temporally by administration of doxycycline.
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